The Manufacturers Life Insurance Company Acquires 50,039 Shares of Novo Nordisk A/S $NVO

The Manufacturers Life Insurance Company raised its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 36.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 187,246 shares of the company’s stock after acquiring an additional 50,039 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Novo Nordisk A/S were worth $6,881,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently bought and sold shares of the company. Godfrey Financial Associates Inc. bought a new stake in Novo Nordisk A/S during the fourth quarter valued at about $25,000. Scarborough Advisors LLC bought a new position in shares of Novo Nordisk A/S during the 1st quarter valued at approximately $26,000. WealthCollab LLC increased its holdings in Novo Nordisk A/S by 93.5% in the 4th quarter. WealthCollab LLC now owns 538 shares of the company’s stock worth $27,000 after acquiring an additional 260 shares in the last quarter. Maseco LLP purchased a new position in Novo Nordisk A/S during the fourth quarter valued at approximately $29,000. Finally, Jackson Grant Investment Advisers Inc. bought a new position in shares of Novo Nordisk A/S in the fourth quarter worth approximately $29,000. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Price Performance

NYSE:NVO opened at $44.48 on Thursday. The firm has a market capitalization of $198.60 billion, a price-to-earnings ratio of 10.88, a PEG ratio of 4.03 and a beta of 0.76. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.56. The business has a 50 day simple moving average of $46.96 and a 200-day simple moving average of $45.12. Novo Nordisk A/S has a 1 year low of $35.12 and a 1 year high of $64.16.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Tuesday, June 30th. The company reported $0.94 earnings per share for the quarter. Novo Nordisk A/S had a return on equity of 61.20% and a net margin of 35.36%.The company had revenue of $11.98 billion for the quarter. Equities analysts forecast that Novo Nordisk A/S will post 3.39 EPS for the current year.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk beat second-quarter expectations, with adjusted sales rising 7% at constant exchange rates and adjusted operating profit increasing 11%. The company also raised its full-year sales and operating-profit outlook, citing continued demand for Wegovy and Ozempic, higher-dose injections and broader GLP-1 volume growth. Novo Nordisk’s Q2 profit beats forecasts, raises outlook
• Positive Sentiment: A Dutch court granted Novo a preliminary injunction against Ceban over an unapproved compounded semaglutide nasal spray, ordering the company to stop infringing activity and remove product listings. The ruling could help protect Novo’s semaglutide intellectual property and branded-product demand. Novo Nordisk wins Dutch court injunction
• Neutral Sentiment: CEO Mike Doustdar said Novo will prioritize faster internal research and smaller “bolt-on” acquisitions rather than transformational mergers. The strategy may conserve capital, but it also leaves investors looking for stronger pipeline evidence. Novo Nordisk not currently in a position to pursue large-scale M&A
• Negative Sentiment: Sales of the oral Wegovy pill were weaker than investors expected, raising concerns about the product’s launch trajectory and pricing economics. Analysts also noted that some quarterly strength came from rebate adjustments and other potentially temporary factors. Novo Nordisk’s raised forecast fails to change the debate over its obesity business
• Negative Sentiment: A setback in the late-stage CagriSema obesity-and-diabetes program weakened confidence in Novo’s next-generation pipeline. Investors are concerned that future products may not be sufficient to offset patent expirations, price reductions and intensifying competition from Lilly. Lilly climbs, Novo falls as obesity drug battle intensifies
• Negative Sentiment: Eli Lilly’s competing GLP-1 franchise delivered a 48% revenue increase to nearly $23 billion, substantially exceeding estimates. The result intensified concerns that Lilly is widening its commercial lead and capturing more of the fast-growing weight-loss market. Eli Lilly stock jumps as GLP-1 sales widen Novo lead

Wall Street Analyst Weigh In

NVO has been the topic of a number of analyst reports. HSBC restated a “hold” rating on shares of Novo Nordisk A/S in a research note on Monday, July 6th. Zacks Research lowered Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a research note on Monday, July 13th. Nordea Equity Research raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Friday, June 19th. Weiss Ratings reissued a “sell (d+)” rating on shares of Novo Nordisk A/S in a report on Monday, July 20th. Finally, Citigroup restated a “neutral” rating on shares of Novo Nordisk A/S in a research note on Monday, July 20th. Five analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $65.56.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.